[
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "CeRNAs sponge miRNAs, preventing them from exerting their normal function of inhibiting protein-coding mRNA translation through MRE complementarity (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Immunotherapy\n\nExosomal ncRNA(s)\nDrug\nRole\nMechanism\nClinical Evidence and Status\nReference\n\n\n\n\nmiR-1246,miR-155\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[85]\n\n\nmiR-567\nTrastuzumab\nEnhancement of trastuzumab sensitivity\nInhibiting autophagy via ATG5 suppression\nyes, downregulated\n[86]\n\n\nSNHG14\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nyes, upregulated\n[77]\n\n\nAGAP2-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nN/A\nno\n[73]\n\n\nAFAP1-AS1\nTrastuzumab\nEnhancement of trastuzumab resistance\nPromoting ERBB2 translation via AUF1 binding\nyes, upregulated\n[72]\n\n\nHormonal Therapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\n\n\nReference\n\n\n\nmiR-221, miR-222\nTamoxifen\nEnhancement of tamoxifen resistance\nNegatively regulating p27 and ERα\nno\n[81]\n\n\nmiR-205\nTamoxifen\nEnhancement of tamoxifen resistance\nInhibiting apoptosis via E2F1 downregulation\nno\n[68]\n\n\nmiR-181a-2\nTamoxifen\nEnhancement of tamoxifen resistance\nDownregulating ERα and activating PI3K/AKT signaling\nno\n[87]\n\n\nUCA1\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nno\n[80]\n\n\nHOTAIR\nTamoxifen\nEnhancement of tamoxifen resistance\nN/A\nyes, upregulated\n[75]\n\n\ncirc_UBE2D2, miR-200a-3p\nTamoxifen\nEnhancement of tamoxifen resistance\nmiR-200a-3p sponging, leading to alterations in cell viability, EMT, and ERα status\nno\n[71]\n\n\nChemotherapy\n\n\n\nExosomal ncRNA(s)\n\n\nDrug\n\n\nRole\n\n\nMechanism\n\n\nClinical Evidence\n\n\nReference\n\n\n\nmultiple miRNAs\nDocetaxel\nEnhancement of docetaxel resistance\nN/A\nno\n[82]\n\n\nmiR-23b\nDocetaxel\nEnhancement of docetaxel resistance\nInducing metastatic breast cancer cell dormancy via suppressing MARCKS\nyes, upregulated\n[84]\n\n\nmiR-134\nCisplatin\nEnhancement of cisplatin sensitivity\nNegatively regulating STAT5B, Hsp90, and Bcl-2\nyes, downregulated\n[88]\n\n\nmiR-222\nAdriamycin\nEnhancement of adriamycin resistance\nN/A\nno\n[79]\n\n\nmiR-222/223\nCarboplatin\nEnhancement of carboplatin resistance\nN/A\nno\n[83]\n\n\nmiR-1246\nDocetaxel, Epirubicin, Gemcitabine\nEnhancement of docetaxel, epirubicin, and gemcitabine resistance\nNegatively regulating Cyclin-G2\nyes, upregulated\n[32]\n\n\nmiR-126a\nDoxorubicin\nEnhancement of doxorubicin resistance\nInducing IL-13+ Th2 cells, promoting angiogenesis, and enhancing cell viability via S100A8/A9 upregulation\nno\n[78]\n\n\nmiR-155\nDoxorubicin, Paclitaxel\nEnhancement of doxorubicin, and paclitaxel resistance\nN/A\nno\n[76]\n\n\nmiR-423-5p\nCisplatin\nEnhancement of cisplatin resistance\nN/A\nno\n[74]\n\n\nmiR-378a-3p,miR-378d\nDoxorubicin, Paclitaxel (neoadjuvant)\nEnhancement of doxorubicin and paclitaxel resistance\nActivation of WNT and NOTCH stemness pathways via DKK3 and NUMB suppression. \nyes, upregulated\n[69]\n\n\nHOTAIR\nNeoadjuvant chemotherapy\nEnhancement of chemoresistance\nN/A\nyes, upregulated\n[75]\n\n\nH19\nDoxorubicin\nEnhancement of doxorubicin resistance\nN/A\nyes, upregulated\n[70]\n\n\n\nOpen in a new tabIn order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In order to confirm that exosomal ncRNAs are the mediators of drug resistance, several studies have adopted the strategy of co-culturing drug-sensitive cells with drug-resistant cells (Figure 2A) or in drug-resistant-cells-derived conditioned media (Figure 2B) in an attempt to demonstrate the exosomal ncRNA-mediated switch from drug sensitivity to resistance [32,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe breast cancer exosomal lncRNA/circRNA-miRNA-target axis.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "After manually curating the literature, miRNAs (hsa-miR-503 [34], hsa-miR-330-5p [25], hsa-miR-16-5p [102], hsa-miR-106a-5p [107], hsa-miR-370 [35], hsa-miR-637 [55], and hsa-miR-200a-3p [71]) were obtained and were sponged by their respective lncRNAs/circRNAs (XIST, SNHG3, SNHG16, HAND2-AS1, circFOXK2, circPSMA1, and circUBE2D2) in the BC exosomal axis (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "This miRNA set was used as an input for the miRTargetLink tool, where the authors sought after genes that are strongly experimentally validated to be targeted by a minimum of two miRNAs from our miRNA set, ending up with a set of 20 strong validated genes (Figure 4).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "A set of 117 shared pathways were obtained, containing BC, integrated BC, and ErbB signaling pathways (Figure 5), and this is supportive of the implication of the exosomal non-coding RNA axis in BC pathology.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Interestingly, the BC pathway was found to be one of the significant KEGG pathways, where 8 of the 20 total genes were found to be implicated in BC pathogenesis at different levels, subtypes, and signaling pathways (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "In addition, information on the number of publications, along with signature publications and the discovery timeline of exosomal ncRNAs in BC, are presented in (Figure 7).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  }
]